The Foreign Corrupt Practices Act Initiative in Pharmaceutical and Device Industry

May 17, 2010
New York, NY

FCPA and International Anti-Corruption for Life Science Companies

Reportedly 8 out of 10 life science companies are under investigation for corrupt practices stemming from the pre and post-approval research, sales and marketing activities involving foreign markets.

As the Department of Justice gathers unprecedented resources in their fight against corruption in the life science industry, prepare your company and clients by gaining the valuable strategies and solutions developed by the premiere FCPA legal and compliance industry experts.

Meet the prosecutors and strategize with top FCPA counsel at the only FCPA and anti-corruption event designed for life sciences.

Government enforcers and in-house compliance and legal counsel will share the critical components and practical advice for establishing and fortifying your compliance program to withstand intense multijurisdictional scrutiny.

Meet the Speakers

Kirk Ogrosky
Arnold & Porter
Subscribe Link

Email Disclaimer